{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:06:02Z","timestamp":1784289962410,"version":"3.55.0"},"reference-count":16,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,6,27]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Fuch\u2019s heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler\u2019s sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.<\/jats:p>","DOI":"10.1136\/bcr-2025-271450","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:40:19Z","timestamp":1784288419000},"page":"e271450","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of spontaneous hyphema in Fuch\u2019s heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-7060","authenticated-orcid":false,"given":"Gerry","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"Northern Sydney Local Health District, St Leonards, New South Wales, Australia"},{"name":"Royal North Shore Hospital, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liane","family":"Papantoniou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"Northern Sydney Local Health District, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"Northern Sydney Local Health District, St Leonards, New South Wales, Australia"},{"name":"Royal North Shore Hospital, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"Northern Sydney Local Health District, St Leonards, New South Wales, Australia"},{"name":"Royal North Shore Hospital, St Leonards, New South Wales, Australia"},{"name":"The University of Sydney Northern Clinical School, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026071704401171000_19.7.e271450.1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.survophthal.2019.10.003","article-title":"A literature review on Fuchs uveitis syndrome: An update","volume":"65","author":"Sun","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.2","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1007\/s00417-024-06502-0","article-title":"Clinical characteristics of viral-associated Fuchs uveitis syndrome and Posner-Schlossman syndrome in a Chinese population","volume":"262","author":"Liu","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00133733","article-title":"Amsler\u2019s sign associated significantly with Fuch\u2019s heterochromic cyclitis (FHC)","volume":"19","author":"Bloch-Michel","year":"1995","journal-title":"Int Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.62.10.715"},{"key":"2026071704401171000_19.7.e271450.5","doi-asserted-by":"crossref","first-page":"999804","DOI":"10.3389\/fmed.2022.999804","article-title":"Factors associated with low prevalence of Fuchs\u2019 uveitis syndrome in Japan","volume":"9","author":"Yoneda","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026071704401171000_19.7.e271450.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2007.05.008"},{"key":"2026071704401171000_19.7.e271450.7","doi-asserted-by":"crossref","first-page":"1405261","DOI":"10.3389\/fmed.2024.1405261","article-title":"The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-analysis","volume":"11","author":"He","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026071704401171000_19.7.e271450.8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/ICU.0000000000001151","article-title":"Medical and surgical management of neovascular glaucoma","volume":"36","author":"Yun","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11892-022-01491-y","article-title":"Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review","volume":"22","author":"Zehden","year":"2022","journal-title":"Curr Diab Rep"},{"key":"2026071704401171000_19.7.e271450.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0640","article-title":"Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"139","author":"Ngo Ntjam","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque","year":"2014","journal-title":"PLoS One"},{"key":"2026071704401171000_19.7.e271450.12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jamaophthalmol.2026.0460","article-title":"Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction","volume":"144","author":"Bordbar","year":"2026","journal-title":"JAMA Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00417-013-2312-9","article-title":"Surgical management of secondary glaucoma in Fuchs\u2019 heterochromic iridocyclitis","volume":"251","author":"You","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026071704401171000_19.7.e271450.14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.12688\/f1000research.15244.1","article-title":"Fuchs heterochromic iridocyclitis-associated glaucoma: a retrospective comparison of primary Ahmed glaucoma valve implantation and trabeculectomy with mitomycin C","volume":"7","author":"Esfandiari","year":"2018","journal-title":"F1000Res"},{"key":"2026071704401171000_19.7.e271450.15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115576","article-title":"The Application of Rho Kinase Inhibitors in the Management of Glaucoma","volume":"25","author":"Liu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026071704401171000_19.7.e271450.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070544","article-title":"Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect In Vivo","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:40:21Z","timestamp":1784288421000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bcr-2025-271450"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271450","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}